NEW YORK (Reuters Health) – An individualized risk communication tool, Predict Prostate, leads to more realistic perceptions about survival, thereby facilitating treatment decisions for newly diagnosed...

A novel radiopharmaceutical has been shown to boost survival when added to standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease had progressed after...

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six...